Q1 2023 Results
Company overview
Innovation: Pipeline overview
Financial review
Financial performance
Conclusions
Appendix
Innovation: Clinical trials
References
Abbreviations
INNOVATION
Novartis pipeline in Phase 2
Solid Tumors
Code
AAA601
Hematology
Name
23 lead indications
Mechanism
BCR-ABL inhibitor
Name
Mechanism
Indication(s)
Code
Lutathera®
Radioligand therapy target SSTR GEPNET, pediatrics:
ABL001
1L ES-SCLC
INC424
Scemblix®
Jakavi®
JAK1/2 inhibitor
Glioblastoma
JDQ443
JDQ443
KRAS inhibitor
NSCLC and CRC (mono and/or combo)
LNP023
iptacopan
CFB inhibitor
NIS793
niseovkitug
TGFB inhibitor
1L metastatic colorectal cancer
MBG453
sabatolimab
TNO155 TNO155
SHP2 inhibitor
Solid tumors
PHE885 PHE885
PKC412
RydaptⓇ
YTB323 rapcabtagene autoleucel
Cardiovascular
Code
Name
TIM3 antagonist
BCMA cell therapy
Multi-targeted kinase inhibitor
CD19 CAR-T
Indication(s)
Chronic myeloid leukemia, 2L, pediatrics
Acute GVHD, pediatrics
Chronic GVHD, pediatrics
Immune thrombocytopenia
Unfit acute myeloid leukemia
Acute myeloid leukemia, maintenance
4L multiple myeloma
Acute myeloid leukemia, pediatrics
1L high-risk large B-cell lymphoma
Immunology
Code
Name
CFZ533
iscalimab
Mechanism
CD40 inhibitor
CMK389 CMK389
IL-18 inhibitor
DFV890 DFV890
LNA043 LNA043
NLRP3 inhibitor
ANGPTL3 agonist
LOU064
remibrutinib
BTK inhibitor
LRX712 LRX712
MAS825 MAS825
Indication(s)
Sjögren's
Hidradenitis suppurativa
Atopic dermatitis
Knee osteoarthritis
Familial cold auto-inflammatory syndrome
Knee osteoarthritis
Osteoarthritis (combos)
Food allergy
Hidradenitis suppurativa
Sjögren's
Osteoarthritis
NLRC4-GOF indications
Hidradenitis suppurativa
CFZ533 iscalimab
LNP023 iptacopan
MBL949 MBL949
ATP modulator
TIN816 TIN816
XXB750 XXB750
Others
Code
Name
Global Health
KAE609 cipargamin
Mechanism
CD40 inhibitor
CFB inhibitor
NPR1 agonist
Indication(s)
Lupus nephritis
Lupus nephritis
Obesity related diseases
Acute kidney injury
Hypertension
Mechanism
Lead indication
Indication(s)
MHV370 MHV370
QUC398 QUC398
VAY736
YTB323
ianalumab
rapcabtagene autoleucel
Neuroscience
Code
Name
ADAMTS5 inhibitor
BAFF-R inhibitor
CD19 CAR-T
Sjögren's
Mixed connective tissue disease
Osteoarthritis
Autoimmune hepatitis
Lupus Nephritis
Mechanism
Indication(s)
KLU156
LXE408
Ganaplacide +
lumefantrine
LXE408
QMF149 Atectura®
SEG101 AdakveoⓇ
Respiratory & Allergy
CMK389 CMK389
LTP001 LTP001
Ophthalmology
LNP023 iptacopan
SAF312 Libvatrep
Malaria, uncomplicated
PfATP4 inhibitor
Malaria, severe
Malaria, uncomplicated
Non-artemisinin plasmodium
falciparum inhibitor
Proteasome inhibitor
Combo
P-selectin inhibitor
IL-18 inhibitor
SMURF1 inhibitor
CFB inhibitor
Gene therapy - Complement
factor I modulation
TRPV1 antagonist
Visceral leishmaniasis
Asthma, pediatrics
Sickle cell disease, pediatrics
Pulmonary sarcoidosis
Pulmonary arterial hypertension
Idiopathic pulmonary fibrosis
iAMD
Geographic atrophy
Chronic ocular surface pain
BLZ945 sotuletinib
DLX3131 minzasolmin
CSF-1R inhibitor
Amyotrophic lateral sclerosis
Alpha-synuclein Inhibitor
Parkinson's disease
MIJ821 onfasprodil
NR2B negative allosteric
modulator
Major depressive disorder with acute suicidal ideation or behavior
PPY9882 PPY988
1. DLX313 is the Novartis compound code for UCB0599.
2. Gyroscope acquisition.
36 Investor Relations | Q1 2023 Results
U NOVARTIS | Reimagining MedicineView entire presentation